Ann: Palla Pharma Investor Presentation - FY19 Results & Outlook, page-3

A bit of a mixed report really. Some good - revenue up, gross profit up. API revenue is looking very good.

I particularly DIDN'T like the 'we would had xx EBITDA if not for this, this and this' on page 11. Normalised EBITDA they call it, but aren't these issues a part of doing business? French customer order deferral, UK customer order deferral, CMO early termination. If not for the really, really fast bowling, I would've opened the batting for Australia!